Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review

Abstract

Diabetes mellitus (DM) is a major risk factor for ischemic stroke. Moreover, patients with DM suffer more severe strokes and have worse functional outcome following an acute stroke than patients without DM. In this context, data from animal studies and emerging evidence from clinical studies suggest that incretin-based antihyperglycemic agents might exert beneficial effects in patients with DM who suffer ischemic stroke. It appears that these agents exert neuroprotective actions that might both reduce infarct size and promote recovery. The present review summarizes the evidence on the potential role of incretin-based antihyperglycemic agents in the management of acute ischemic stroke.

Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future

“…A recently published review in which several preclinical studies were examined, it was concluded that using GLP-1 agonists improve functional outcome after ischemic stroke. It’s unknown whether these results are valid for humans in clinical practice[82].…”

Synthesis and Biological Evaluation of Substituted Pyrazole‐Fused Oleanolic Acid Derivatives as Novel Selective α‐Glucosidase Inhibitors

“…Diabetes mellitus mainly consists of two clinical forms, Type 1 and Type 2 diabetes, especially the latter accounting for about 90 % of all diabetics worldwide. [1] Type 2 diabetes is a chronic metabolic disorder featuring hyperglycemia, [2] which can also cause other disease complications, [3] e. g., stroke, renal, cardiac and hepatic disorders. [4,5] In 2019, about 403 million diabetics were diagnosed worldwide with one death every five seconds, and the number of patients was estimated to be 700 million by 2045.…”